Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes
Diabetes, Obesity and Metabolism, 07/06/2012
Katz LB et al. – The studies provide evidence of limited glucose lowering and incretin activity for JNJ–38431055 in subjects with type 2 diabetes mellitus (T2DM).



